4/14
Negative
Late treatment study
et al., BMJ 2020, 369, doi:10.1136/bmj.m1849 (Peer Reviewed)
Hydroxych loroquine in patients with COVID-19: an open-label, randomized, controlled trial
150 patients very late stage RCT. No significant difference. More symptomatic relief with HC Q. Treatment very late, average 16.6 days after symptom onset. Data favorable to HC Q was deleted in the second version, see analysis [1].